Last updated: September 24, 2026
PedvaxHIB is the principal U.S. product matching the description "Haemophilus b conjugate vaccine, meningococcal protein conjugate." It is Merck's monovalent Haemophilus influenzae type b vaccine using polyribosylribitol phosphate, or PRP, conjugated to meningococcal group B outer-membrane protein complex, known as PRP-OMP. The product remains commercially relevant because of its early immunogenicity in infants, but its financial profile is mature, low-growth, and heavily dependent on public-sector procurement rather than branded price expansion.
Merck does not separately report PedvaxHIB revenue. Its sales are aggregated within broader vaccine reporting, making product-level revenue and margin estimates unavailable from public filings. The product's economic value is better assessed through U.S. birth-cohort demand, government contracts, supply reliability, combination-vaccine substitution, and the absence of meaningful remaining patent exclusivity.
What product is the meningococcal protein conjugate Haemophilus b vaccine?
The product is PedvaxHIB, manufactured by Merck & Co., Inc. It is a liquid, monovalent Hib vaccine for children aged 2 through 71 months.
| Attribute |
PedvaxHIB |
| Active antigen |
Haemophilus influenzae type b PRP |
| Carrier protein |
Meningococcal group B outer-membrane protein complex |
| Conjugate designation |
PRP-OMP |
| Dosage form |
Liquid injectable suspension |
| Primary schedule |
Two doses at 2 and 4 months |
| Booster |
One dose at 12-15 months |
| U.S. indication |
Children 2-71 months |
| U.S. sponsor |
Merck Sharp & Dohme LLC |
| FDA pathway |
Biologics license application |
| Main commercial channel |
Pediatric practices, pharmacies, state programs, and Vaccines for Children |
| Key substitutes |
ActHIB, Hiberix, and combination vaccines such as Pentacel |
PedvaxHIB differs from ActHIB and Hiberix because the carrier protein is meningococcal outer-membrane protein rather than tetanus toxoid. The PRP-OMP platform generates an earlier antibody response after the first dose, a characteristic that supported its use in young infants and high-risk populations.[1]
What is the FDA regulatory status of PedvaxHIB?
PedvaxHIB is an FDA-licensed pediatric Hib vaccine. The product is not a new molecular entity and does not depend on current clinical innovation for its regulatory position. The FDA-approved labeling identifies the product as a three-dose series, with two primary doses and a booster dose.[1]
The CDC recommends routine Hib vaccination for children younger than 5 years. Hib vaccination is generally not recommended for healthy children aged 5 years or older, except in specific medical-risk circumstances.[2]
FDA and public-health milestones
| Milestone |
Date or status |
| Hib conjugate vaccines introduced in the United States |
Late 1980s |
| PedvaxHIB commercial availability |
Established product; exact original launch date is not material to current exclusivity |
| Routine infant immunization |
CDC-recommended |
| Vaccines for Children eligibility |
Included when supplied under applicable federal contracts |
| Current regulatory basis |
Existing BLA and FDA-approved labeling |
| Biosimilar pathway |
Not applicable in the conventional oncology or autoimmune sense |
| Generic substitution |
Not governed by an ANDA-style generic pathway |
Hib vaccines are regulated as biologics. A competing manufacturer must generally obtain its own biologics license or pursue an appropriate interchangeable or biosimilar framework, but the practical competitive issue is product licensure and procurement qualification rather than conventional generic substitution.
How large is the market for Hib vaccines?
The U.S. Hib market is a stable, prevention-driven market tied to the annual infant birth cohort. U.S. births were approximately 3.6 million in 2023, creating a recurring addressable population for primary and booster vaccination.[3] The number of commercial doses is higher than the birth count because most children receive multiple doses.
The market has four structural characteristics:
- Demand is medically necessary and schedule-based.
- Volume is concentrated in infants and toddlers.
- Government purchasing has substantial influence over net prices.
- Product choice is increasingly shaped by combination vaccines.
The U.S. market is not a conventional prescription market. Parents do not typically select PedvaxHIB based on brand advertising. Pediatricians, health systems, state immunization programs, insurers, and federal purchasing programs determine most product selection.
Approximate demand framework
A simplified U.S. birth-cohort model produces a recurring annual need of roughly 8 to 11 million Hib-containing doses across monovalent and combination products, depending on catch-up vaccination, schedule adherence, product mix, wastage, and the share of combination vaccines. This is an addressable-dose estimate, not reported PedvaxHIB sales.
PedvaxHIB captures only part of that demand because:
- ActHIB and Hiberix compete in the monovalent segment.
- Pentacel and other combination products include Hib antigen.
- Some providers prefer fewer injections and use combination vaccines.
- Public programs may award contracts based on price, supply, and portfolio coverage.
- Hib coverage is high, which limits growth from untreated demand.
What drives the financial trajectory of PedvaxHIB?
PedvaxHIB has the financial profile of a mature essential vaccine rather than a growth biologic. Revenue is likely driven by unit volume, tender awards, contract pricing, and manufacturing continuity. Price increases may occur, but they are constrained by public-payer negotiations and competitive procurement.
Revenue drivers
| Driver |
Effect on PedvaxHIB |
| U.S. birth cohort |
Creates recurring baseline demand |
| CDC and VFC purchasing |
Supports volume but limits net price |
| Pediatric vaccination rates |
Determines realized demand |
| Combination-vaccine adoption |
Can reduce monovalent demand |
| Supply disruptions |
Can sharply increase or reduce short-term sales |
| Provider preference for two-dose primary series |
Supports PRP-OMP differentiation |
| International Hib programs |
Expand public-health demand but generally at lower prices |
| Patent status |
No meaningful current exclusivity premium |
| Manufacturing cost |
Important because volumes are moderate and prices are controlled |
Merck reports vaccine revenue at an aggregated level. Its vaccine portfolio includes major products such as Gardasil, ProQuad, M-M-R II, Varivax, and other products. PedvaxHIB is not separately identified in Merck's annual reports, so company-reported vaccine revenue cannot be used as a proxy for PedvaxHIB revenue.[4]
Financial trajectory by phase
| Period |
Commercial profile |
| Launch and adoption |
Rapid uptake as Hib conjugate vaccination entered routine pediatric care |
| 1990s |
Expansion of routine immunization and strong volume growth |
| 2000s |
Mature-market phase; competition and combination vaccines increased |
| 2010s |
Stable essential-product demand with limited innovation-based pricing |
| 2020-2022 |
Routine pediatric disruption and catch-up effects during the COVID-19 period |
| 2023 onward |
Normalization of pediatric vaccination, with procurement and supply as primary variables |
The product's likely current economic contribution is modest relative to Merck's largest vaccine brands. Its value is strategic: maintaining a complete pediatric vaccine portfolio, supporting public-sector relationships, and preserving manufacturing scale in a mature vaccine category.
What patents protect the meningococcal protein conjugate Hib vaccine?
The core commercial patent estate for PRP-OMP Hib vaccination is effectively mature. The technology originated decades ago, and any foundational composition, conjugation, formulation, or manufacturing patents associated with the original product would generally have expired or become commercially immaterial by 2026.
PedvaxHIB does not appear to depend on a modern, long-duration patent thicket comparable to newer monoclonal antibodies, long-acting injectables, or complex delivery systems.
Patent and exclusivity assessment
| Protection category |
Current assessment |
| Core PRP-OMP composition |
Foundational protection is expired or no longer commercially limiting |
| Conjugation chemistry |
Older platform rights are unlikely to block current competition |
| Product formulation |
No publicly evident late-life formulation barrier supporting a new exclusivity period |
| Manufacturing process |
Process know-how may remain confidential, but it is not equivalent to market exclusivity |
| FDA biologics exclusivity |
Original product exclusivity has expired |
| Patent term extension |
Any historic extension would not create current commercial exclusivity |
| Trade secrets |
Potentially relevant to yield, consistency, and scale-up |
| Regulatory exclusivity |
No current period comparable to a newly licensed biologic |
What is the Orange Book status of PedvaxHIB?
PedvaxHIB is a biologic licensed under a BLA, not a conventional small-molecule product approved under an NDA. The FDA Orange Book is therefore not the principal source for its product-specific exclusivity analysis.
The relevant regulatory records are:
- FDA biologics licensing and product information;
- FDA-approved prescribing information;
- CDC immunization schedules;
- CDC vaccine price and contract documents;
- state and federal procurement records;
- competing biologics licenses.
An Orange Book-style patent listing is not the primary commercial barrier for PedvaxHIB. Competitors would not normally enter through an ordinary ANDA referencing a listed small-molecule drug patent.
When does PedvaxHIB lose exclusivity?
PedvaxHIB has already lost effective commercial exclusivity. Its current position is based on regulatory approval, manufacturing capability, provider familiarity, supply reliability, and procurement economics.
There is no evident current patent cliff comparable to the loss of exclusivity for a recently launched biologic. A new competitor would face operational and regulatory requirements, but not a significant remaining composition-of-matter patent barrier.
Paragraph IV challenges and generic entry
A conventional Paragraph IV challenge is unlikely to be the relevant entry mechanism because PedvaxHIB is a biologic vaccine rather than an NDA-based small-molecule product. The commercial threat would more likely come from:
- a separately licensed competing Hib vaccine;
- an interchangeable or biosimilar-type biologic pathway, if applicable;
- a combination vaccine displacing monovalent use;
- a tender competitor winning public-sector volume;
- a manufacturer with lower-cost global production.
No major publicly established Paragraph IV litigation is central to PedvaxHIB's current market position.
Which companies challenge PedvaxHIB?
The principal competitive set includes Sanofi and GSK in the U.S. Hib market.
| Company |
Product or product family |
Competitive position |
| Merck |
PedvaxHIB |
PRP-OMP monovalent Hib vaccine |
| Sanofi |
ActHIB; Pentacel includes Hib component |
Major monovalent and combination competitor |
| GSK |
Hiberix |
Monovalent Hib competitor |
| Other manufacturers |
Combination or regional Hib products |
Relevant mainly outside the U.S. or through public tenders |
Competition is based less on patent differentiation than on:
- availability;
- contracted net price;
- delivery reliability;
- cold-chain performance;
- provider familiarity;
- compatibility with state and federal purchasing;
- ability to supply combination products.
How strong is the patent estate for PedvaxHIB?
The patent estate is weak as a current exclusivity instrument but the commercial franchise remains defensible through manufacturing and procurement barriers.
Patent strength: low
The foundational science is old, and the product has no apparent active patent barrier capable of preventing an independently licensed competitor from entering.
Manufacturing strength: moderate to high
Conjugate vaccines require reproducible control of:
- polysaccharide molecular size;
- activation and conjugation;
- carrier-protein quality;
- antigen content;
- residual reagents;
- sterility;
- potency;
- lot-to-lot consistency.
These requirements create practical barriers. They do not create patent exclusivity, but they can lengthen development and regulatory timelines.
Commercial strength: moderate
PedvaxHIB benefits from a recognized brand, established clinical use, and inclusion in a national pediatric vaccination infrastructure. That position is vulnerable to combination vaccines and public tender competition.
What formulation and manufacturing IP protects the product?
The product's most important non-patent assets are likely process controls and manufacturing know-how. These can include conjugation conditions, purification procedures, control of molecular-weight distribution, analytical assays, and scale-up parameters.
Publicly disclosed labeling identifies the antigen and carrier platform but does not provide a complete manufacturing process. Process know-how may therefore retain value even after patent expiration.
The practical distinction is important:
- A patent can exclude competitors for a defined term.
- Manufacturing know-how can improve yield, quality, and regulatory reliability.
- Know-how cannot prevent a competitor from developing an independent process.
- A licensed competitor still must establish comparability, safety, potency, and manufacturing consistency.
What litigation affects PedvaxHIB?
No major current patent litigation appears to define the U.S. commercial outlook for PedvaxHIB. The product's risk profile is operational rather than litigation-driven.
The more relevant legal and regulatory risks are:
- product-liability claims;
- manufacturing deviations;
- recalls or shortages;
- contract disputes;
- procurement protests;
- changes in federal vaccine purchasing;
- regulatory action involving manufacturing quality.
A lack of major patent litigation is consistent with the product's mature technology and expired foundational exclusivity.
What generic launch risks exist?
The probability of a classic generic launch is low because vaccines do not follow a simple small-molecule generic model. The more realistic entry scenarios are:
Scenario 1: Stable mature market
PedvaxHIB retains a steady share of monovalent Hib demand. Revenue remains broadly flat, with changes driven by birth rates, immunization compliance, and public contracts.
Scenario 2: Combination-vaccine substitution
Combination vaccines capture more pediatric visits and reduce the need for monovalent PedvaxHIB. This is the clearest structural downside risk.
Scenario 3: Procurement displacement
A competitor wins a federal or state contract through lower net pricing or superior supply capacity. Unit volume declines without any patent event.
Scenario 4: Supply disruption
A manufacturing interruption at a competitor increases demand for PedvaxHIB. The reverse also applies: a PedvaxHIB shortage can transfer demand to ActHIB, Hiberix, or combination products.
Scenario 5: Global low-price expansion
International public-health programs increase volume but dilute average selling prices. This scenario supports manufacturing utilization more than revenue growth.
How does PedvaxHIB compare with ActHIB and Hiberix?
| Category |
PedvaxHIB |
ActHIB |
Hiberix |
| Carrier protein |
Meningococcal group B outer-membrane protein complex |
Tetanus toxoid |
Tetanus toxoid |
| Primary infant schedule |
Two doses before booster |
Three-dose primary series before booster |
Three-dose primary series before booster |
| Core differentiation |
Earlier response and shorter primary series |
Broad established use |
Established monovalent alternative |
| Main commercial risk |
Combination-vaccine substitution |
Higher injection burden |
Procurement and availability |
| Patent-based advantage |
None material today |
None material today |
None material today |
| Buying decision |
Price, supply, schedule, contracting |
Price, supply, schedule, contracting |
Price, supply, schedule, contracting |
PedvaxHIB's two-dose primary series can have operational value for adherence and early protection. Its disadvantage is that monovalent Hib products compete against combination products that reduce injection counts across the entire pediatric schedule.
What licensing deals affect the product?
No major current licensing transaction appears to drive the product's market value. The commercial rights are associated with Merck's established vaccine franchise. The relevant economic arrangement is more likely to be procurement contracting than a publicly disclosed in-licensing or royalty transaction.
Merck's financial disclosures do not identify a separate PedvaxHIB licensing stream or product-level royalty burden.[4] Any historic technology licenses related to conjugation science would not appear to create a visible current financial constraint based on publicly available product reporting.
What is the revenue exposure for Merck?
PedvaxHIB is unlikely to be a material standalone revenue driver for Merck compared with Gardasil and other major vaccine products. Its financial importance is portfolio-based.
Revenue exposure assessment
| Exposure |
Assessment |
| Absolute revenue |
Not separately disclosed and likely modest within Merck's vaccine segment |
| Growth potential |
Low |
| Margin profile |
Potentially attractive if manufacturing scale is efficient, but public pricing limits upside |
| Downside risk |
Combination substitution, tenders, shortages, and declining birth cohorts |
| Strategic value |
Supports pediatric vaccine portfolio and public-sector relationships |
| Patent-cliff risk |
Low because effective exclusivity has already expired |
| Litigation risk |
Low relative to newer patented biologics |
| Operational risk |
More significant than patent risk |
Key Takeaways
- The product matching the description is PedvaxHIB, Merck's PRP-OMP Hib vaccine.
- Its market is mature, recurring, and tied to the U.S. infant birth cohort.
- Merck does not separately disclose PedvaxHIB revenue.
- Current financial performance depends on public procurement, supply reliability, and product mix.
- The core patent estate is effectively expired and does not provide meaningful current exclusivity.
- A conventional Paragraph IV challenge is not the expected entry mechanism.
- The strongest competitive threat is combination-vaccine substitution, not patent expiry.
- Manufacturing know-how and regulatory execution create practical barriers, but not durable market exclusivity.
- ActHIB and Hiberix remain the principal U.S. monovalent competitors.
- PedvaxHIB's strategic value exceeds its likely standalone revenue importance.
FAQs
Is PedvaxHIB still commercially available?
Yes. PedvaxHIB remains an FDA-licensed Hib vaccine for children aged 2 through 71 months, subject to commercial supply and distribution conditions.
Does PedvaxHIB have a biosimilar competitor?
No major U.S. biosimilar competitor is publicly established as the principal market challenger. Competition comes from separately licensed Hib vaccines and combination products.
Is PedvaxHIB listed in the Orange Book?
The product is regulated under a BLA, so its core exclusivity analysis is not based on an Orange Book patent listing in the same manner as an NDA-approved small-molecule drug.
What is the biggest commercial risk to PedvaxHIB?
The largest structural risk is displacement by combination vaccines. Procurement losses and manufacturing interruptions are the main short-term risks.
Does the PRP-OMP carrier create a lasting patent advantage?
No. The carrier platform may provide clinical and schedule differentiation, but the foundational technology is mature and does not appear to create meaningful current patent exclusivity.
References
-
U.S. Food and Drug Administration. (2024). PedvaxHIB prescribing information. Merck Sharp & Dohme LLC.
-
Centers for Disease Control and Prevention. (2024). Child and adolescent immunization schedule by age. U.S. Department of Health and Human Services.
-
Centers for Disease Control and Prevention, National Center for Health Statistics. (2024). Births: Final data for 2023. U.S. Department of Health and Human Services.
-
Merck & Co., Inc. (2024). 2023 annual report. Merck & Co., Inc.
